AP3607A - Substituted imidazopyridazines - Google Patents
Substituted imidazopyridazinesInfo
- Publication number
- AP3607A AP3607A AP2013006790A AP2013006790A AP3607A AP 3607 A AP3607 A AP 3607A AP 2013006790 A AP2013006790 A AP 2013006790A AP 2013006790 A AP2013006790 A AP 2013006790A AP 3607 A AP3607 A AP 3607A
- Authority
- AP
- ARIPO
- Prior art keywords
- substituted imidazopyridazines
- imidazopyridazines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Paper (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10176134 | 2010-09-10 | ||
EP11075022 | 2011-02-04 | ||
EP11170771 | 2011-06-21 | ||
EP11170775 | 2011-06-21 | ||
PCT/EP2011/065368 WO2012032031A1 (en) | 2010-09-10 | 2011-09-06 | Substituted imidazopyridazines |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2013006790A0 AP2013006790A0 (en) | 2013-04-30 |
AP3607A true AP3607A (en) | 2016-02-26 |
Family
ID=44545741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2013006790A AP3607A (en) | 2010-09-10 | 2011-09-06 | Substituted imidazopyridazines |
Country Status (38)
Country | Link |
---|---|
US (1) | US9255100B2 (ru) |
EP (1) | EP2614063B1 (ru) |
JP (1) | JP5824050B2 (ru) |
KR (1) | KR20140032337A (ru) |
CN (1) | CN103370318B (ru) |
AP (1) | AP3607A (ru) |
AR (1) | AR082946A1 (ru) |
AU (1) | AU2011298844B2 (ru) |
BR (1) | BR112013005679A2 (ru) |
CA (1) | CA2810755A1 (ru) |
CO (1) | CO6720961A2 (ru) |
CR (1) | CR20130102A (ru) |
CU (1) | CU24187B1 (ru) |
CY (1) | CY1117352T1 (ru) |
DK (1) | DK2614063T3 (ru) |
DO (1) | DOP2013000054A (ru) |
EA (1) | EA023420B1 (ru) |
EC (1) | ECSP13012752A (ru) |
ES (1) | ES2568220T3 (ru) |
HK (1) | HK1187623A1 (ru) |
HR (1) | HRP20160360T1 (ru) |
HU (1) | HUE028771T2 (ru) |
IL (1) | IL225058A (ru) |
MA (1) | MA34516B1 (ru) |
ME (1) | ME02389B (ru) |
MX (1) | MX2013002713A (ru) |
MY (1) | MY185139A (ru) |
NZ (1) | NZ607904A (ru) |
PE (1) | PE20131164A1 (ru) |
PL (1) | PL2614063T3 (ru) |
RS (1) | RS54661B1 (ru) |
SA (1) | SA111320735B1 (ru) |
SG (1) | SG188417A1 (ru) |
SI (1) | SI2614063T1 (ru) |
TW (1) | TWI541243B (ru) |
UY (1) | UY33598A (ru) |
WO (1) | WO2012032031A1 (ru) |
ZA (1) | ZA201301756B (ru) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
ES2671748T3 (es) * | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
CA2867061A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
ME02651B (me) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corp | Substituisana triciklična jedinjenja kao inhibitori fgfr |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
CA2889919C (en) * | 2012-11-16 | 2021-08-17 | University Health Network | Pyrazolopyrimidine compounds |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
CA2909207C (en) | 2013-04-19 | 2021-11-02 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9586958B2 (en) | 2013-06-11 | 2017-03-07 | Bayer Pharma Aktiengesellschaft | Prodrug derivatives of substituted triazolopyridines |
MA38657A1 (fr) * | 2013-06-13 | 2018-05-31 | Bayer Pharma AG | Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer |
CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物,其制备方法及用途 |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
KR102420508B1 (ko) * | 2014-02-21 | 2022-07-13 | 프로스트 바이오로직, 아이엔씨. | 암 및 증식성 장애들의 치료를 위한 유사분열억제성 아마이드들 |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
TW201613927A (en) | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN107567503B (zh) | 2015-04-17 | 2022-03-22 | 荷兰转化研究中心有限责任公司 | 用于ttk抑制剂化疗的预后生物标记 |
WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
EP3383796B1 (en) * | 2015-12-04 | 2020-09-16 | ExxonMobil Research and Engineering Company | Emm-28, a novel synthetic crystalline material, its preparation and use |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
ES2945108T3 (es) | 2016-07-18 | 2023-06-28 | Univ Health Network | Formas sólidas de inhibidor de TTK |
CN110753560B (zh) * | 2017-04-11 | 2022-07-26 | 斯特劳曼控股公司 | 牙科植入物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
WO2023113477A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2273369T3 (es) | 1996-08-28 | 2007-05-01 | Pfizer Inc. | Derivados 6,5 heterobiciclicos sustituidos. |
DK1277754T3 (da) | 2000-04-27 | 2005-11-14 | Astellas Pharma Inc | Imidazopyridinderivater |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CA2628455A1 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
WO2008130951A1 (en) * | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
EP2240488B1 (en) | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
EP2424537B1 (en) | 2009-04-29 | 2015-07-08 | Bayer Intellectual Property GmbH | Substituted imidazoquinoxalines |
TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
EP2547680B1 (en) | 2010-03-18 | 2015-08-05 | Bayer Intellectual Property GmbH | Imidazopyrazines |
JP5824040B2 (ja) | 2010-06-01 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピラジン |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
CN103403006B (zh) | 2010-12-17 | 2015-11-25 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪 |
CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
CN103443100B (zh) | 2010-12-17 | 2016-03-23 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪 |
CA2821819A1 (en) | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
JP2014503521A (ja) | 2010-12-17 | 2014-02-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類 |
-
2011
- 2011-08-25 TW TW100130542A patent/TWI541243B/zh not_active IP Right Cessation
- 2011-09-06 MY MYPI2013700375A patent/MY185139A/en unknown
- 2011-09-06 SG SG2013016480A patent/SG188417A1/en unknown
- 2011-09-06 HU HUE11751910A patent/HUE028771T2/en unknown
- 2011-09-06 AU AU2011298844A patent/AU2011298844B2/en not_active Ceased
- 2011-09-06 NZ NZ607904A patent/NZ607904A/en not_active IP Right Cessation
- 2011-09-06 CU CUP2013000033A patent/CU24187B1/es active IP Right Grant
- 2011-09-06 MX MX2013002713A patent/MX2013002713A/es active IP Right Grant
- 2011-09-06 JP JP2013527575A patent/JP5824050B2/ja not_active Expired - Fee Related
- 2011-09-06 EA EA201390339A patent/EA023420B1/ru not_active IP Right Cessation
- 2011-09-06 AP AP2013006790A patent/AP3607A/xx active
- 2011-09-06 US US13/822,175 patent/US9255100B2/en not_active Expired - Fee Related
- 2011-09-06 PL PL11751910T patent/PL2614063T3/pl unknown
- 2011-09-06 ME MEP-2016-63A patent/ME02389B/me unknown
- 2011-09-06 BR BR112013005679A patent/BR112013005679A2/pt not_active IP Right Cessation
- 2011-09-06 SI SI201130761A patent/SI2614063T1/sl unknown
- 2011-09-06 EP EP11751910.8A patent/EP2614063B1/en active Active
- 2011-09-06 PE PE2013000392A patent/PE20131164A1/es not_active Application Discontinuation
- 2011-09-06 ES ES11751910.8T patent/ES2568220T3/es active Active
- 2011-09-06 CA CA2810755A patent/CA2810755A1/en not_active Abandoned
- 2011-09-06 KR KR1020137009011A patent/KR20140032337A/ko not_active Application Discontinuation
- 2011-09-06 DK DK11751910.8T patent/DK2614063T3/en active
- 2011-09-06 MA MA35720A patent/MA34516B1/fr unknown
- 2011-09-06 CN CN201180054217.5A patent/CN103370318B/zh not_active Expired - Fee Related
- 2011-09-06 RS RS20160221A patent/RS54661B1/en unknown
- 2011-09-06 WO PCT/EP2011/065368 patent/WO2012032031A1/en active Application Filing
- 2011-09-07 SA SA111320735A patent/SA111320735B1/ar unknown
- 2011-09-08 UY UY0001033598A patent/UY33598A/es unknown
- 2011-09-09 AR ARP110103294A patent/AR082946A1/es unknown
-
2013
- 2013-03-05 IL IL225058A patent/IL225058A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01756A patent/ZA201301756B/en unknown
- 2013-03-08 DO DO2013000054A patent/DOP2013000054A/es unknown
- 2013-03-08 CR CR20130102A patent/CR20130102A/es unknown
- 2013-03-08 EC ECSP13012752 patent/ECSP13012752A/es unknown
- 2013-03-08 CO CO13047157A patent/CO6720961A2/es active IP Right Grant
-
2014
- 2014-01-24 HK HK14100807.7A patent/HK1187623A1/zh not_active IP Right Cessation
-
2016
- 2016-04-08 HR HRP20160360TT patent/HRP20160360T1/hr unknown
- 2016-04-12 CY CY20161100294T patent/CY1117352T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3607A (en) | Substituted imidazopyridazines | |
DK3342786T3 (en) | Anti-dll3-antistof | |
HK1171452A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
AP3107A (en) | 5-Alkynyl-pyrimidines | |
EP2566479A4 (en) | AZA-INDAZOLES | |
EP2640189A4 (en) | 3-deutero-pomalidomide | |
DK3466977T3 (en) | Anti-vla-4-antistoffer | |
EP2651505A4 (en) | ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION | |
EP2641891A4 (en) | PKC ACTIVATOR- | |
HK1188782A1 (en) | Substituted sodium-1h-pyrazole-5-olate 1h--5- | |
AU4536P (en) | TB01 Tibouchina urvilleana | |
AU4937P (en) | FlatinsulGL Myoporum insulare | |
AU4931P (en) | FlatwaxDarkGL Chamelaucium uncinatum | |
AU4822P (en) | FlatwaxwhiteGL Chamelaucium uncinatum | |
AU2010194V (en) | CalpenGL Calothamnus quadrifidus | |
AU2010165V (en) | Silversunrise Conostylis candicans | |
GB201000765D0 (en) | Koolkilt | |
GB201000799D0 (en) | 2velcrose | |
GB201000706D0 (en) | Kilthanger | |
GB201000547D0 (en) | Jurasic | |
GB201000426D0 (en) | Earbling | |
GB201000203D0 (en) | Formits | |
GB201000246D0 (en) | Head-kase | |
GB201000262D0 (en) | Flexishaft | |
GB201000166D0 (en) | Doordeadman |